[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endocrine-system-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endocrine-system-diseases":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,49,91,124,161,190,216,243,274,301,374,405,440,487,530],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100054307","phase-2-metabolic-modulation-to-enhance-insulin-sensitivity-and-mitochondrial-function-in-type-1-diabetes-metmod-t1d-100054307",false,"NCT07699380","METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)","MetMod-T1D","Inclusion Criteria:\n\n1. Adults ≥18 years to \\\u003C70 years of age with established T1D (duration ≥1 year)\n2. Currently on insulin therapy (multiple daily injections or insulin pump)\n3. HbA1c \\\u003C9.5%\n4. BMI 18.5-40 kg\u002Fm2\n5. On stable dose of RASB or statin, if indicated\n6. Willing and able to comply with all study procedures\n\nExclusion Criteria:\n\n1. History of pancreatic disease (including pancreatitis) or pancreatic surgery\n2. History of cardiovascular disease or stroke within the past 6 months\n3. History of heart failure per New York Heart Association criteria\n4. History of severe edema or salt restriction requirement\n5. Biliary disease or pathologies that may alter enterohepatic circulation of bile acids\n6. Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73m²\n7. Liver disease (ALT\u002FAST \\>3x upper limit of normal \\[ULN\\])\n8. Pregnancy, breastfeeding, or planning pregnancy during the study period\n9. Known hypersensitivity to study drug components\n10. Abnormal baseline ECG\n11. Use of off label medications that affect insulin sensitivity within the past 1 month (e.g., metformin, GLP-1RA, SGLT2i, pioglitazone)\n12. Chronic use of anticoagulants\n13. Use of bile acid sequestering agents, inhibitors of bile acid transporters, bile acid derivatives, aluminum-based antacids, probenecid, pan-HDAC inhibitors, phase 2 metabolizing enzymes (e.g., uridine diphosphate glucuronosyl transferases), phase 1 metabolizing enzymes other than cytochrome P450 enzymes (CYPs), and OATP1B3\n14. Use of substrates of CYP1A2, CYP2C8, CYP2B6, CYP3A4, Organic Anion transporter 1, P-glycoprotein, and Breast Cancer Resistance Protein\n15. History of severe hypoglycemia requiring assistance within the past 3 months\n16. History of diabetic ketoacidosis (DKA) within the past 3 months\n17. Personal or family history of breast cancer or ovarian cancer\n18. Current participation in another clinical trial\n19. Any condition(s) found by the study team and confirmed with the Investigator that make it unsafe to participate","ALL","18 Years","69 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The study is a randomized, double-blind, parallel-group clinical trial to examine the effects of 24 weeks of oral AMX0035 (sodium phenylbutyrate + taurursodiol) versus placebo in 60 adults with Type 1 Diabetes (T1D) (n=30 per arm). Enrollment will be distributed equally between the University of Washington and Amsterdam University Medical Center\u002FDiabetes Center Amsterdam. Participants will be recruited through diabetes research registries, local T1D clinics, and community outreach.",[27,28,29,30,31,32,33,34,35],"Type 1 Diabetes (T1D)","Metabolic Diseases","Glucose Metabolism Disorders","Endocrine System Diseases","Autoimmune Diseases","Immune System Diseases","Diabetes Melletus, Type 1","Nutritional and Metabolic Diseases","Combination Therapy","RECRUITING","2026-07-09",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":21},"2026-06",{"date":44,"type":21},"2029-12",{"name":46,"class":47},"University of Washington","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":77,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100637347","phase-3-a-study-of-orforglipron-ly3502970-in-participants-with-type-2-diabetes-who-observe-ramadan-fasting-100637347","NCT07613307","A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting","A Phase 3b, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Orforglipron in Adult Participants With Type 2 Diabetes Who Observe Ramadan Fasting (ACHIEVE-RAM)","ACHIEVE-RAM","Inclusion Criteria:\n\n* Have a clinical diagnosis of T2D based on the World Health Organization (WHO) classification or other locally applicable diagnostic standards.\n* Have an HbA1c value of at least 7.0% (53 millimoles per mole (mmol\u002Fmol)) to less than 9.5% (91 mmol\u002Fmol) at screening.\n* Intend to be compliant with the fast during the Ramadan period.\n* Have had stable body weight self-reported change of 5 kilograms (kg) or lower during the 90 days prior to screening.\n* Have body mass index (BMI) of 25 kilograms per meter square (kg\u002Fm2) or higher at screening.\n\nExclusion Criteria:\n\n* Have any form of diabetes other than T2D, including type 1 diabetes (T1D), gestational diabetes, latent autoimmune diabetes, maturity-onset diabetes of the young, and medication-induced diabetes\n* Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.\n* Have a history of chronic or acute pancreatitis any time prior to screening\n* Have evidence of a significant, uncontrolled endocrine abnormality, for example, thyrotoxic or adrenal crises, in the opinion of the investigator\n* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years.\n* Have a history of cholecystectomy (surgically removed gallbladder)\n* Have New York Heart Association Functional Classification IV congestive heart-failure.","65 Years",{"count":59,"type":21},130,[61],"PHASE3","The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a minimum of 7 in clinic visits and 4 virtual visits.",[64,65,29,66,34,30,67,68,69,70,71,72,73,74,75,76],"Diabetes Mellitus, Type 2","Diabetes Melletus","Metabolic Disorders","Feeding Behavior","Behavior","Fasting","Glucagon-Like Peptide-1 Receptor","Glucagon-Like Peptide Receptors","Receptors, G-Protein-Coupled","Receptors, Cell Surface","Membrane Proteins","Proteins","Receptors, Peptide",[78,69],"Ramadan","NOT_YET_RECRUITING","2026-06-18",{"date":82,"type":40},"2026-06-23",{"date":84,"type":21},"2026-07",{"date":86,"type":21},"2027-05",{"name":88,"class":89},"Eli Lilly and Company","INDUSTRY",37,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100599246","phase-3-a-phase-3-randomized-clinical-trial-to-investigate-the-safety-and-efficacy-of-palopegteriparatide-at-doses-greater-than-30-gday-in-adult-participants-with-hypoparathyroidism-100599246","NCT07081997","A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg\u002FDay in Adult Participants With Hypoparathyroidism","A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Efficacy of Palopegteriparatide Administered Subcutaneously Daily at Doses Greater Than 30 μg\u002FDay in Adult Participants With Hypoparathyroidism","PaTHway60","Inclusion criteria:\n\n1. Males and females, ≥18 years of age at the time of providing informed consent\n2. Participants with postsurgical chronic hypoparathyroidism (HP), or auto-immune, genetic, or idiopathic HP, for at least 26 weeks\n3. Receiving doses of palopegteriparatide at or above 30 µg\u002Fday\n\n   For individuals receiving 30 µg\u002Fday: evidence that dose is insufficient to keep serum calcium in the normal range, defined as:\n\n   Documented hypocalcemia within 12 weeks prior to Screening; and\u002For Standing dose of calcitriol ≥0.25 μg\u002Fday, and \u002F or (elemental) calcium ≥1500 mg\u002Fday (e.g., calcium citrate, calcium carbonate etc.) for at least 4 weeks prior to Screening\n\n   For individuals receiving 33 µg\u002Fday or greater: no requirement for documented hypocalcemia or minimum doses of calcitriol or elemental calcium\n4. Confirmation of laboratory parameters (Central and Local) within 2 weeks of screening visit and prior to randomization:\n\n25(OH) vitamin D levels of 20 - 80 ng\u002FmL (49 - 200 nmol\u002FL) and Magnesium level in the normal range, or just below the normal range i.e.: ≥1.3 mg\u002FdL (≥0.53 mmol\u002FL) and Albumin-adjusted or ionized sCa level in the normal range or just below the normal range\n\n* Albumin-adjusted sCa 7.8 - 10.6 mg\u002FdL (or 1.95 - 2.64 mmol\u002FL)\n* Ionized sCa 4.40 - 5.29 mg\u002FdL (1.10 - 1.32 mmol\u002FL)\n\n  5\\. BMI 17- 40 kg\u002Fm2 at Screening\n\n  6\\. If ≤25 years of age, radiological evidence of epiphyseal closure based on locally interpreted X-ray of non-dominant wrist and hand\n\n  7\\. eGFR ≥30 mL\u002Fmin\u002F1.73 m2 during Screening using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula\n\nExclusion criteria\n\n1. Impaired responsiveness to PTH (pseudohypoparathyroidism), which is characterized as PTH-resistance, with elevated PTH levels in the setting of hypocalcemia\n2. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HP\n3. Use of loop diuretics, phosphate binders (other than calcium supplements), digoxin, lithium, methotrexate, biotin \\>30 µg\u002Fday, or systemic corticosteroids (other than as replacement therapy)\n4. Use of thiazide diuretic within 4 weeks prior to the 24-hour urine collection scheduled to occur within 1 week prior to Visit 1\n5. Use of PTH-like drugs other than palopegteriparatide (whether commercially available or through participation in an investigational trial), including PTH(1-34), or other N-terminal fragments, analogs of PTH or PTH-related protein, or PTH1R biased agonists within 4 weeks prior to Screening\n6. Use of drugs known to influence calcium and bone metabolism within 12 weeks prior to Screening\n7. Use of osteoporosis therapies other than bisphosponate known to influence calcium and bone metabolism within 2 years prior to Screening. Note: use of bisphosphonate (oral or intravenous \\[IV\\] is not exclusionary\n8. Non-hypocalcemic seizure disorder with occurrence of a seizure within 26 weeks prior to Screening.\n9. Increased risk for osteosarcoma\n10. Women who are pregnant, intend to become pregnant, or are lactating\n11. Male who has a female partner who intends to become pregnant or is of childbearing potential and is unwilling to use adequate contraceptive methods during the trial\n12. Diagnosed drug or alcohol dependence within 3 years prior to Screening\n13. Chronic or severe cardiac disease within 26 weeks prior to Screening\n14. Cerebrovascular accident within 5 years prior to Screening.\n15. Within 26 weeks prior to Screening: acute colic due to nephrolithiasis, or acute gout\n16. Participation in any other interventional trial in which receipt of investigational drug or device other than palopegteriparatide occurred within 8 weeks (or within 5.5 times the half-life of the investigational drug) (whichever comes first) prior to Screening.\n17. Known allergy or sensitivity to PTH or any of the excipients \\[metacresol, mannitol, succinic acid, NaOH\u002F(HCl)\\] of the investigational product",{"count":100,"type":21},36,[61],"This trial has a duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg\u002Fday. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg\u002Fday in adults with hypoparathyroidism. The trial will be conducted in the US.",[104,30,105],"Hypoparathyroidism","Parathyroid Diseases",[104,107,108,109,110,111,112,113],"Parathyroid Hormone","TransCon PTH","PTH(1-34)","Prodrug","Sustained Release","Parathyroid Hormone Replacement Therapy","Palopegteriparatide","2026-05-01",{"date":116,"type":40},"2026-05-04",{"date":118,"type":40},"2026-04-16",{"date":120,"type":21},"2028-06",{"name":122,"class":89},"Ascendis Pharma Bone Diseases A\u002FS",3,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":135,"conditions":136,"keywords":143,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":4},"100624764","telehealth-music-therapy-for-adults-with-endocrine-disorder-and-depression-100624764","NCT07413874","Telehealth Music Therapy for Adults With Endocrine Disorder and Depression","Telehealth Music Therapy for Adults With Endocrine System Based Autoimmune Disease and a Depressive Disorder: An Intervention Development Study","Inclusion Criteria:\n\n* self-reported depression\n* self-reported autoimmune endocrine disease\n* 18-65 years of age\n* have a device that supports the Zoom platform (camera and audio)\n\nExclusion Criteria:\n\n* intellectual or developmental disability\n* no auto-immune disease\n* no depression\n* lack of access to device\n* under the age of 18 years\n* over the age of 65 years",{"count":132,"type":21},10,[134],"NA","The goal of this clinical trial is to explore if a telehealth music therapy intervention helps with quality of life, depression symptoms, anxiety symptoms. It will also explore the participants' relationship to music. The main questions it aims to answer are:\n\n* Refine and tailor the music therapy intervention to fit the specific needs of adults living with an autoimmune disease and depression.\n* Examine the feasibility of the study protocol to support a future full-scale trial\n* Examine how music therapy impacts quality of life, depression symptoms, and anxiety symptoms\n* Explore how music therapy impacts one's relationship to music\n\nParticipants will:\n\n* have a short interview where you'll fill out a questionnaire with some basic information, answers about your depression, quality of life, and potential anxiety, and a question about how you feel about music at the start and end of the sessions\n* attend 8 weekly sessions, approximately 30-45 minutes each, with a board certified music therapist over telehealth\u002FZoom\n* answer a few questions about the music therapy intervention",[137,138,139,140,141,142,30],"Type 1 Diabetes","Hashimoto Disease","Graves Disease","Addison Disease","Autoimmune Polyglandular Syndrome Type III","Depression",[144,145,146,147,148,149,150,151],"type 1 diabetes","music therapy","behavioral health","psychosocial","diabetes","behavioral intervention","quality of life","telehealth","2026-02-10",{"date":154,"type":40},"2026-02-17",{"date":156,"type":21},"2026-02-01",{"date":158,"type":21},"2026-12-31",{"name":160,"class":47},"Appalachian State University",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":167,"sex":16,"minAge":168,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":172,"conditions":173,"keywords":177,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":187,"locationsCount":189},"100619731","the-diabeat-study-insulin-delivery-technologies-and-eating-behaviours-in-people-with-type-1-diabetes-100619731","NCT07348432","The diabEAT Study: Insulin dElivery Technologies And eaTing Behaviours in People With Type 1 Diabetes","Inclusion Criteria:\n\n* 12 years of age or older\n* Living in Canada\n* Living with type 1 diabetes for more than 1 year\n* Using at least 2 insulin injections per day or using an insulin pump\n* Using current insulin delivery system for 3 months or more\n\nExclusion Criteria:\n\n* Are pregnant or currently are breastfeeding\n* Don't speak French or English\n* Does not have a smart phone (to download applications)",true,"12 Years",{"count":170,"type":21},106,"OBSERVATIONAL","Type 1 diabetes is an autoimmune health condition that requires daily injections of insulin. Insulin allows the body to use energy from carbohydrates in food. Disordered eating behaviours, like restricting food intake to lose body weight, are more common in women and people with type 1 diabetes, compared to those without because they must practice carbohydrate counting. Carbohydrate counting means identifying, measuring, and planning carbohydrate intake to match insulin dosage. New technologies, such as automated insulin delivery (AID) systems adjust insulin delivery in a blood sugar responsive manner. AID is rapidly replacing conventional insulin delivery like injections or non-automated insulin pumps since it reduces management burden and improves blood sugar levels. It is not known if AID reduces food management and disordered eating behaviours. This study aims to: 1. investigate the relationship between AID and eating behaviours according to gender for youth (12 to 17 years), and adults (18 years and older). 2. Determine the limit of carbohydrate counting inaccuracy to maintain stable blood sugar levels according to insulin delivery method (AID, injections, or pumps). It is hypothesized that those who use AID will have lower disordered eating behaviours and will maintain stable blood sugar levels while allowing for higher carbohydrate counting inaccuracy. This will be a cross-sectional cohort study of people with type 1 diabetes who are 12 years of age or over. Participants will be recruited through the BETTER registry and social medias across Canada. This research is needed to improve nutrition guidelines for type 1 diabetes in the context of new technologies like AID. Evidence from this study may reduce food management burden, lower the risk of disordered eating behaviours, and prevent eating disorders and medical complications.",[174,175,176,137,31,30],"Insulin Dependent Diabetes Mellitus","Feeding and Eating Disorders","Eating Behavior",[178,179,180,137],"Automated Insulin Delivery","Disordered Eating Behaviours","Nutrition","2026-01-12",{"date":183,"type":40},"2026-01-16",{"date":185,"type":40},"2024-07-29",{"date":114,"type":21},{"name":188,"class":47},"McGill University",1,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":167,"sex":16,"minAge":196,"maxAge":197,"enrollmentInfo":198,"targetDuration":200,"studyType":171,"phases":4,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":4},"100608081","prospective-cohort-of-integrated-traditional-chinese-and-western-medicine-in-china-100608081","NCT07196917","Prospective Cohort of Integrated Traditional Chinese and Western Medicine in China","Inclusion Criteria:\n\nAge: Participants aged 30 to 74 years\n\nPhysical Functionality: Free from severe physical disabilities impacting mobility or communication, with preserved ability to comprehend and respond to study procedures\n\nInformed Consent: Capable of providing written informed consent voluntarily after receiving full study disclosure\n\nExclusion Criteria:\n\nResidents living in functional areas (e.g., work sheds, military units, student dormitories, nursing homes, etc.)\n\nIndividuals unable to communicate normally","30 Years","74 Years",{"count":199,"type":21},1000000,"10 Years","To further explore the application prospects of integrated Traditional Chinese and Western medicine in chronic disease prevention and control and health management, this study intends to establish a large, prospective, integrated Traditional Chinese and Western medicine cohort in Hubei Province. This study will conduct long-term follow-up and multi-dimensional data collection to systematically reveal the associations between Traditional Chinese Medicine (TCM) constitution types and chronic diseases, the aging process, and multi-morbidity, thereby developing an integrated health management strategy with local characteristics. This study will fill the current gap in systematic evidence linking TCM constitutions to the prevalence of modern diseases, providing a solid demographic and biological foundation for the integrated development of Traditional Chinese and Western medicine. It will also contribute to meeting the needs for early disease warning, early intervention, and personalized care under the \"Healthy China\" strategic goal.",[203,204,205,30,206],"Cardiovascular Diseases","Respiratory Tract Diseases","Cancer","Death","2025-09-29",{"date":209,"type":40},"2025-10-02",{"date":211,"type":21},"2025-10-01",{"date":213,"type":21},"2027-12-31",{"name":215,"class":47},"Huazhong University of Science and Technology",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":242},"100521437","implementation-of-support-in-the-care-of-adults-living-with-type-1-diabetes-100521437","NCT06069583","Implementation of Support in the Care of Adults Living With Type 1 Diabetes","Using the Support Online Platform for Self-management Education of Adults Living With Type 1 Diabetes as Part of Usual Care or Independently: an Implementation Study","Inclusion Criteria:\n\n* Diagnosis of T1D (including LADA - latent autoimmune diabetes in adults)\n* Have access to Internet\n* Use of an active email address\n* Comprehension of English or French\n* Live in Canada\n\nExclusion Criteria:\n\n\\- Unable to use the Support platform",{"count":224,"type":21},322,[134],"The investigators will conduct a trial to evaluate if an online training and support platform can help adults living with type 1 diabetes (T1D) in their diabetes self-management. Investigators will compare a group that has access to the \"Support\" platform through their usual medical care to a group that accesses the platform independently. The first group will be recruited through four participating clinics in the province of Quebec (Canada). The second group will be composed of adults living with T1D across Canada. Participants will have access to the platform for 12 months and will be asked to complete online questionnaires at the beginning and after 6 and 12 months, and share their glucose reader data with the research team. A subgroup of participants as well as healthcare professionals from the four clinics will be invited to participate in an individual interview aiming to understand the barriers and facilitators of integration \"Support\" in clinical care.",[137,228,30,31,32],"Metabolic Disease",[230,231,232,233,144],"self-management education","Hemaglobin A1c","Online education","adults","2025-09-22",{"date":236,"type":40},"2025-09-25",{"date":238,"type":40},"2024-05-05",{"date":240,"type":21},"2027-10",{"name":188,"class":47},4,{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":16,"minAge":251,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":256,"conditions":257,"keywords":261,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":272,"locationsCount":242},"100509239","support-t-online-training-in-youth-living-with-type-1-diabetes-transitioning-to-adult-care-100509239","NCT05910840","Support-t Online Training in Youth Living With Type 1 Diabetes Transitioning to Adult Care","Support-t, an Online Training and Peer Support Platform to Accompany Youth Living With Type 1 Diabetes Transitioning to Adult Healthcare","Support-t","Inclusion Criteria:\n\n* Adolescents with a clinical diagnosis of T1D\n* 14-16 years of age\n* Receiving diabetes care at one of 4 university teaching hospital-based pediatric diabetes clinics in Quebec: Montreal Children's Hospital-McGill University Health Centre, Centre hospitalier universitaire de Sherbrooke, Le Copain-Hôpital de Gatineau, Centre Hospitalier Universitaire de Québec\n* Having access to internet\n* Having an active email address\n* Fluent in English or French\n\nExclusion Criteria:\n\n* Severe neurocognitive disabilities\n* Patients with conditions associated with shortened erythrocyte survival, such as hemolytic anemia or other conditions associated with inaccurate HbA1c","14 Years","16 Years",{"count":254,"type":21},200,[134],"The investigators will conduct a randomized controlled trial (RCT) to examine how an online training and peer support platform could help the preparation to transition to adult care. Among 14-16 year old youth with Type 1 Diabetes (T1D), the investigators aim to assess the effect of an online training and peer support platform (Support-t) integrated in usual care, compared with usual care on Hemoglobin A1c (HbA1c), adverse outcomes and psychosocial measures during the preparation for transition to adult care. The investigators will conduct a multi-site, parallel group, blinded (outcome assessors, data analysts), superiority RCT of adolescents with T1D (14-16 years of age) followed at one of 4 university teaching hospital-based pediatric diabetes clinics in the province of Quebec.",[258,259,260,228,30,31,32],"Diabetes Mellitus","Diabetes Mellitus, Type 1","Glucose Metabolism Disorders (Including Diabetes Mellitus)",[262,263,264,265,231,266,267],"Transition Care","Pediatric","Adolescent","Education","Self-management","Randomized Controlled Trial",{"date":236,"type":40},{"date":270,"type":40},"2024-10-07",{"date":240,"type":21},{"name":273,"class":47},"Anne-Sophie Brazeau",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":283,"conditions":284,"keywords":288,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":300},"100481074","rare-and-atypical-diabetes-network-100481074","NCT05544266","Rare and Atypical Diabetes Network","RADIANT","Inclusion Criteria:\n\nThe following criteria or phenotypes will be considered for suspecting \"atypical\" participants:\n\n* Type 2 diabetes diagnosed at a time when the individual was prepubertal or non-obese\n* Mendelian pattern, especially with early onset (\\\u003C18 years old)\n* Syndromic (multiple systems involved)\n* Lipodystrophic\n* Extremes of BMI\n* \"Mitochondrial\" characteristics (e.g., myopathy, hearing deficits)\n* Non-progressive\n* Rapidly progressive (\"fulminant\")\n* Low insulin requirements (\\\u003C0.5 u\u002Fkg\u002Fday)\n* Cyclical hyperglycemia with periods of remission\n* Lean persons with polycystic ovarian syndrome (PCOS)\n* History of gestational diabetes (GDM) when lean\n* Lean insulin-resistant persons\n* If islet autoantibodies and beta-cell function parameters have been measured (where \"A\" = islet cell autoantibodies, \"B\" = beta-cell function):\n\noA-B- (i.e., lacking islet autoimmunity makers and lacking beta cell function) oA-B+ with unprovoked DKA at initial presentation (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but presenting with unprovoked DKA) oA-B+ of very young onset (pre-pubertal) (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but very early onset T2D-like phenotype)\n\nExclusion Criteria:\n\n* Those with high likelihood of typical type 1, typical type 2, known monogenic, or other known secondary forms of diabetes\n* Refusal of consent for genetic testing\n* Islet autoantibody positive (participants who are islet autoantibody positive but present with additional atypical features i.e. syndromic, strong linear family history of diabetes may not be excluded)\n* Women who are currently pregnant",{"count":282,"type":21},2000,"RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes.\n\nThe objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to:\n\n1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes.\n2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes.\n3. Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes.",[258,285,286,29,228,287,30],"Diabetes Mellitus Progression","Glucose Intolerance","Endocrine; Complications",[279,289,290,286],"Atypical Diabetes","Rare Diabetes","2025-08-11",{"date":293,"type":40},"2025-08-14",{"date":295,"type":40},"2020-09-30",{"date":297,"type":21},"2030-09",{"name":299,"class":47},"University of South Florida",13,{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":308,"minAge":17,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":311,"briefSummary":312,"conditions":313,"keywords":333,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":48},"100397880","phase-2-locomotor-training-with-testosterone-to-promote-bone-and-muscle-health-after-spinal-cord-injury-100397880","NCT04460872","Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury","Locomotor Training With Testosterone to Promote Bone and Muscle Health","Inclusion Criteria:\n\n* Men \\>18 years of age\n* Diagnosis of an incomplete SCI involving spinal segments L1 or above or a clinically complete SCI involving spinal segments T2-L1, with upper motor neuron injury signs (i.e., spasticity, hypertonicity) for \\>60-days\n* Low serum total testosterone (\\\u003C300 ng\u002FdL), bioavailable testosterone (\\\u003C110 ng\u002FdL), or free testosterone (\\\u003C46 pg\u002FmL or \\\u003C4.6 ng\u002FdL)\n* Presence of one or more sign or symptom that may be related to low testosterone, including: loss of body hair or reduced shaving, very small testes (\\\u003C6 mL), reduced sexual desire (libido) and activity, decreased spontaneous erections (e.g., morning erections) or erectile dysfunction, breast discomfort or gynecomastia, height loss, low-trauma fracture, or low BMD, hot flushes or sweats, decreased energy, motivation, initiative, or self-confidence, fatigue or irritability, feeling sad or blue, having a depressed mood, or having a persistent low-grade depressive disorder, poor concentration or memory, sleep disturbances or increased sleepiness, mild unexplained anemia (normochromic or normocytic), reduced muscle bulk, strength, or physical performance, Increased body fat or body mass index, any other sign or symptom commonly associated with low testosterone\n* Locomotor dysfunction, definted as self-selected walking pace ≤1.0 m\u002Fs on a 10mWT, either with or without gait devices or braces and with or without assistance, or as self-selected walking pace \\>1.0 m\u002Fs with reliance on a gait device or brace or with highly compensated movement impairments, as identified by a trained observer.\n* Diagnosis of first time SCI including etiology from trauma, vascular, or orthopedic pathology\n* Medically-stable condition that is asymptomatic for conditions that will interfere with the study participation\n* Willingness to administer TRT as instructed by the study staff and to abide by study protocol\n* Documented approval from the study physician verifying medical status\n\nExclusion Criteria:\n\n* Currently participating in another research protocol that may influence study outcomes.\n* Mental state that precludes understanding the study protocol.\n* Life expectancy \\\u003C12-months.\n* History of or current congenital SCI (e.g., Chiari malformation, myelomeningocele, intraspinal neoplasm, Frederich's ataxis) or other degenerative spinal disorder (e.g., spinocerebellar degeneration) that may complicate study procedures\n* Multiple sclerosis, amyotrophic lateral sclerosis, or other neurologic impairment or injury\n* Current prostate, breast, or other organ cancer or a history of prostate or breast cancer\n* Any other diagnosed or treated cancer within the past 24-months, with the exceptions of basal or squamous cell carcinoma of the skin that has been successfully treated\n* Serum prostate-specific antigen (PSA) \\>3.0 ng\u002FmL \\[men treated with 5-alpha reductase inhibitors (e.g., finasteride or dutasteride) are eligible to participate if PSA values are ≤1.5 ng\u002FmL\\]\n* Prostate nodule or induration noted on digital rectal exam (DRE) during screening that tests positive for prostate cancer\n* Currently seeking fertility or expected during the duration of the study\n* Gynecomastia\n* Hematocrit (HCT) \\>49%\n* Any major cardiovascular (CV) event within the last 12-months (defined as a history of acute myocardial infarction, any cardiac revascularization procedure including angioplasty, stenting, or coronary artery bypass grafting, revascularization of the carotid or middle cerebral artery or procedures to treat critical limb ischemia, or hospitalization due to unstable angina, transient ischemic attack, stroke, or peripheral vascular disease)\n* Angina that is not controlled on a current medical regimen (Canadian class II, III, or IV)\n* Poorly compensated congestive heart failure (NYHA class III or IV)\n* Poorly controlled hypertension (consistently measured systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg), while on medications\n* Poorly controlled arrhythmia of any type\n* Severe valvular heart disease\n* Baseline electrocardiogram (ECG) findings such as left bundle branch block or marked ECG abnormalities that would preclude serial screening evaluations for occult ischemic events\n* History of unprovoked deep venous thrombosis (DVT), unprovoked pulmonary embolism, history of recurrent DVT or known thrombophilia\n* LDL cholesterol \\>160 mg\u002FdL with history of any major CV event, defined above, within the last 12-months\n* Major non-CV surgery (e.g., major abdominal or thoracic procedure) within 90-days prior to screening and\u002For a major surgery scheduled at the time of screening\n* Liver enzymes (AST or ALT) \\>1.5 times the normal upper limit\n* Severe or end-stage chronic kidney disease documented by estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\n* Diagnosed, but untreated severe obstructive sleep apnea\n* Lower extremity fracture in the last 12-months (exclusion criterion for participation in LT+TRT group only)\n* Femoral neck, total hip, or lumbar spine t-score below -2.5 or distal femur BMD \\\u003C0.70 g\u002Fcm2, assessed via DEXA at screening (exclusion criterion for participation in LT+TRT group only)\n* Current anticoagulant therapy (contraindication for i.m. injections)\n* Use of any of the following pharmacologic agents in the previous 90-days: any TRT formulation, any compounded or over-the-counter androgenic hormones or androgen precursors, clomiphene, aromatase inhibitors, anti-estrogen or estrogen treatment, or growth hormone\n* Use of anti-resorptive or bone anabolic drug therapy in the previous 180-days\n* Acute use (\\>5-days) of any opioids (e.g., oxycodone, hydrocodone, etc) or systemic glucocorticoids \\>7.5 mg\u002Fd prednisone equivalent (e.g., hydrocortisone 30 mg, methylprednisolone 6 mg, or dexamethasone 1.2 mg) within 1-week before screening visit, except men who are taking these medications for a chronic condition and are anticipated to continue treatment for the study duration\n* Known allergy to any component of the TRT formulation (e.g., sesame oil or cottonseed oil)\n* Any other condition, therapy, lab abnormality, medical or psychiatric conditions, or reason that might pose a risk to the participant, make participation not in the person's best interest, confound the study results (e.g., inability to comply with study requirements), make the participant unsuitable to receive study intervention, or interfere with the person's ability to participate for the entire study duration","MALE",{"count":310,"type":21},21,[24],"This pilot study will determine the feasibility of implementing a combinatory rehabilitation strategy involving testosterone replacement therapy (TRT) with locomotor training (LT; walking on a treadmill with assistance and overground walking) in men with testosterone deficiency and walking dysfunction after incomplete or complete spinal cord injury. The investigators hypothesize that LT+TRT treatment will improve muscle size and bone mineral density in men with low T and ambulatory dysfunction after incomplete or complete SCI, along with muscle fundtion and walking recovery in men with T low and ambulatory dysfunction ater incomplete SCI.",[314,315,316,317,318,319,320,30,321,322,323,324,325,326,327,328,329,330,331,332],"Spinal Cord Injury","Spinal Cord Injuries","Trauma, Nervous System","Wounds and Injury","Central Nervous System Diseases","Spinal Cord Diseases","Gonadal Disorders","Hypogonadism","Genital Diseases, Male","Spinal Cord Trauma","Injuries, Spinal Cord","Walking, Difficulty","Gait Disorders, Neurologic","Locomotion Disorder, Neurologic","Wounds and Injuries","Nervous System Diseases","Testosterone Deficiency","Androgen Deficiency","Hormone Deficiency",[334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,314],"Testosterone","Testosterone enanthate","Testosterone undecanoate","Testosterone 17 beta-cypionate","Methyltestosterone","Androgens","Hormones","Hormone Substitutes, and Hormone Antagonists","Physiologic Effects of Drugs","Pharmacologic Actions","Therapeutic Uses","Anabolic Agents","Testosterone Replacement Therapy","Dual Energy X ray Absorptiometry","Lean Tissue Mass","Body Composition","Muscle Strength","Muscle Mass","Bone Mineral Density","Adipose Tissue","Body Fat","Density, Bone","Bone Formation","Bone Resorption","Bone Density Conservation Agents","Magnetic Resonance Imaging","Walking","Ambulation","Locomotor","Locomotion","Treadmill","2025-05-01",{"date":367,"type":40},"2025-05-06",{"date":369,"type":40},"2021-01-31",{"date":371,"type":21},"2026-06-30",{"name":373,"class":47},"North Florida Foundation for Research and Education",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":403,"locationsCount":48},"100524715","phase-2-extension-study-of-two-doses-of-linsitinib-in-subjects-with-active-moderate-to-severe-thyroid-eye-disease-ted-100524715","NCT06112340","Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)","Inclusion Criteria:\n\n* Subject who completed the 24-week double-mask period of VGN-TED-301 and are proptosis non-responders (\\\u003C 2 mm reduction in proptosis in the study eye) at Week 24 of VGN-TED-301 study or proptosis responders at Week 24 who relapse during the Follow-Up period of VGN-TED-301\n* Subject has not received any treatment for TED since Week 24 of VGN-TED-301\n* Subjects must be euthyroid with the participant's baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine \\[FT4\\] and free triiodothyronine levels \\[FT3\\] \\\u003C50% above or below the normal limits) at Baseline. Every effort should be made to correct mild hypo- or hyperthyroidism promptly and maintain the euthyroid state for the duration of the clinical trial\n* Does not require immediate ophthalmic surgery, radiotherapy to orbits or other ophthalmological intervention at the time of Baseline and is not planning for any such treatment during the course of the study\n\nExclusion Criteria:\n\n* The exclusion criteria of protocol VGN-TED-301 also apply to this extension study.",{"count":382,"type":21},75,[24,61],"The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.",[386,387,30,388,389,390,391,392,393,394,395,396],"Thyroid Eye Disease","Graves Orbitopathy","Eye Diseases","Thyroid Associated Ophthalmopathy","Graves Ophthalmopathy","Thyroid Diseases","Orbital Diseases","Proptosis","IGF1R","Exophthalmos","Hashimoto","2025-02-24",{"date":399,"type":40},"2025-02-25",{"date":401,"type":40},"2023-10-11",{"date":42,"type":21},{"name":404,"class":89},"Sling Therapeutics, Inc.",{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":413,"minAge":168,"maxAge":17,"enrollmentInfo":414,"targetDuration":4,"studyType":22,"phases":415,"briefSummary":416,"conditions":417,"keywords":425,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":189},"100558914","in-person-lifestyle-program-for-black-adolescent-girls-at-risk-for-type-2-diabetes-100558914","NCT06557317","In-Person Lifestyle Program for Black Adolescent Girls at Risk for Type 2 Diabetes","Examining the Preliminary Efficacy of an In-Person Lifestyle Intervention for Black Female Adolescent\u002FCaregiver Dyads at Risk for Type 2 Diabetes Mellitus","BGW In-Person","Inclusion Criteria for adolescent participants:\n\n* 12-18 years of age\n* self-identify as Black or African American\n* have obesity (\\>=95th percentile BMI)\n\nExclusion Criteria for adolescent participants:\n\n* pregnant or within 3 months postpartum.\n* participated in a formal weight management program within 6 months prior to study.\n* currently taking medications or diagnosed with a condition known to influence metabolism, physical activity ability, or cognitive function.\n* have previously undergone bariatric surgery.\n* have type 2 diabetes.\n* unable to speak English or have developmental conditions that interfere with ability to communicate.\n\nInclusion Criteria for caregiver participants:\n\n* 18 years or older.\n* proficiency in speaking English.\n* live in the same household as the adolescent who will also be enrolled.\n* prepares the majority (\\>50%) of meals in the household.\n\nExclusion Criteria for caregiver participants:\n\n* pregnant or within 3 months postpartum.\n* unable to speak English or have developmental conditions that interfere with ability to communicate.","FEMALE",{"count":20,"type":21},[134],"The aim of this study is to look at changes in diabetes-related risk factors in Black adolescent girls who are at risk for type 2 diabetes and their primary female caregiver after both participating in a 12-week in-person lifestyle program.",[418,419,64,420,29,228,30,421,422,423,424,258],"Behavior, Adolescent","Childhood Obesity","Pediatric Obesity","Overweight","Overnutrition","Nutrition Disorders","Body Weight",[426,427,428,429,430],"Adolescents","In-Person Lifestyle Program","Diabetes prevention","Black girls","Obesity","2024-08-14",{"date":433,"type":40},"2024-08-16",{"date":435,"type":21},"2024-08",{"date":437,"type":21},"2024-12-31",{"name":439,"class":47},"Cornell University",{"id":441,"slug":442,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":448,"enrollmentInfo":449,"targetDuration":451,"studyType":171,"phases":4,"briefSummary":452,"conditions":453,"keywords":461,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":486},"100400392","osprey-is-a-post-market-global-multicentre-observational-prospective-registry-100400392","NCT04493632","OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.","OncoSil Pancreatic Cancer Post-marketing Clinical REgistrY (OSPREY)","OSPREY","Inclusion Criteria:\n\n1. Patients with confirmed unresectable locally advanced pancreatic cancer (LAPC).\n2. Patients who undergo OncoSil™ implantation at an eligible treatment facility.\n3. Patients who have completed and signed the Patient Informed Consent Form (PICF) for the OSPREY Patient Registry.\n4. Pancreatic target tumour recommended size of \\\u003C7 cm (longest diameter) and \\\u003C110 cc volume.\n5. A clinically acceptable ECOG performance status.\n6. Patients ≥ 18 years of age at screening.\n7. To commence gemcitabine-based chemotherapy, (per Standard-of-Care are according to the approved prescribing schedule) post Registry enrolment.\n8. Adequate biochemical tests, coagulation profile, haematological, renal, and hepatic function as determined by the Treating Physician.\n\nExclusion Criteria:\n\n1. Patient Informed Consent Form (PICF) has not been completed and signed for the OSPREY Patient Registry.\n2. Patients treated with OncoSil™ within an approved interventional clinical study (company or investigator-sponsored).\n3. Evidence of distant metastases based on review of baseline CT scan.\n4. More than one primary lesion.\n5. In the opinion of the Treating Physician, EUS-directed implantation posing undue patient risk. This includes:\n\n   * where previous EUS-FNA was considered technically too difficult to perform;\n   * imaging demonstrates multiple collateral vessels surrounding or adjacent to the target tumour within the pancreas;\n   * presence (or significant risk) of varices near to the target tumour.\n6. Evidence of radiographic invasion into stomach or duodenum (if not certain, confirmation must be obtained prior to enrolment).\n7. In the setting of recent, clinically significant pancreatitis, implantation is not recommended.\n8. Pregnant or intending to commence a pregnancy within 12-months of the intended date of implantation or breastfeeding.\n9. Patients who have a known history of hypersensitivity to silicon or phosphorous, or any of the OncoSil™ components","90 Years",{"count":450,"type":21},500,"24 Months","The OSPREY Patient Registry has been developed to collect and assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry.\n\nThe Registry data will provide both complementary and contemporary information to the existing clinical data across various countries and will form part of the post-market clinical follow-up activities for OncoSil™. Therefore, the Registry will be implemented only in countries with regulatory (commercial) approval for the OncoSil™ device.",[454,455,456,457,458,459,460,30],"Pancreatic Neoplasm","Digestive System Neoplasm","Neoplasms by Site","Neoplasms","Endocrine Gland Neoplasm","Digestive System Disease","Pancreatic Diseases",[462,463,464,465,466,467,468,469,470,471,472,473,474,475,476],"Pancreatic Cancer","Pancreas","Metastases","Pancreatic tumor","Unresectable","Locally advanced","Implantable","Radiographic","Device","Phosphorous-32","OncoSil™","Brachytherapy","Gemcitabine","Nab-paclitaxel","Abraxane","2024-04-29",{"date":479,"type":40},"2024-04-30",{"date":481,"type":40},"2022-04-12",{"date":483,"type":21},"2027-10-01",{"name":485,"class":89},"OncoSil Medical Limited",9,{"id":488,"slug":489,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":495,"enrollmentInfo":496,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":498,"conditions":499,"keywords":515,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":529},"100435367","spanish-series-of-patients-treated-with-the-radionuclide-lutetium177-100435367","NCT04949282","Spanish Series of Patients Treated With the Radionuclide Lutetium177","SEPTRALU, Spanish Series of Patients Treated With the Radionuclide Lutetium177","SEPTRALU","Inclusion Criteria:\n\n* Written informed consent must be obtained prior to any data collection.\n* Patients must be diagnosed with unresectable or metastatic, progressive, somatostatin receptor positive tumour\n* Aged ≥18 years.\n\nExclusion Criteria:\n\n* None","100 Years",{"count":497,"type":21},5000,"This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.",[500,501,502,503,504,505,506,457,507,508,509,456,510,511,512,513,514,30],"Neuroendocrine Tumors","Intestinal Neoplasms","Pancreatic Neoplasms","Stomach Neoplasms","Neuroectodermal Tumors","Neoplasms, Germ Cell and Embryonal","Neoplasms by Histologic Type","Neoplasms, Nerve Tissue","Gastrointestinal Neoplasms","Digestive System Neoplasms","Endocrine Gland Neoplasms","Digestive System Diseases","Gastrointestinal Disease","Intestinal Diseases","Pancreatic Disease",[516,517,518,519],"GEP-NET","Gastro-Entero-Pancreatic Neuroendocrine Tumour","Luthatera","Somatostatin receptor positive tumour","2022-12-22",{"date":522,"type":40},"2022-12-23",{"date":524,"type":40},"2021-05-10",{"date":526,"type":21},"2035-12-31",{"name":528,"class":47},"Sociedad Española de Medicina Nuclear e Imagen Molecular",20,{"id":531,"slug":532,"hasResults":11,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":538,"enrollmentInfo":539,"targetDuration":4,"studyType":22,"phases":540,"briefSummary":541,"conditions":542,"keywords":543,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":189},"100365554","rt-cgm-in-young-adults-at-risk-of-dka-100365554","NCT04039763","RT-CGM in Young Adults at Risk of DKA","Assessment of the Impact of Real-time Continuous Glucose Monitoring on Glycaemic Control in High-risk Adolescents and Young Adults With Insulin-treated Diabetes","YODA","Inclusion Criteria:\n\n* Adolescents and young adults aged 18-25 years\n* Insulin-treated diabetes \\>12 months (on multiple daily injections or insulin pump therapy)\n* HbA1c \\> 75 mmol\u002Fmol (9%) or 1 or more DKA admissions in the last 12 months or 1 or more admissions with uncontrolled blood glucose levels in the last 12 months.\n* Naïve to RT-CGM - except for short periods for use for diagnosis or monitoring purposes.\n* Use of prior flash glucose monitoring is permittable\n\nExclusion Criteria:\n\n* Chronic kidney disease eGFR \\\u003C30ml\u002Fmin\n* Pregnant or planning pregnancy\n* Breastfeeding\n* Have active malignancy or under investigation for malignancy\n* Severe visual impairment\n* Reduced manual dexterity\n* Unable to participate due to other factors, as assessed by the Chief Investigator","25 Years",{"count":529,"type":21},[134],"Pilot study to evaluate the effect of real time continuous glucose monitoring (RT-CGM) on young-adults with insulin-treated diabetes, who are defined as high risk due to suboptimal HbA1c (blood glucose control) or a history of hospital admissions for high blood glucoses.\n\nHypothesis: RT-CGM provided to young adults with suboptimal blood glucose control, has a beneficial impact on HbA1c and hospital admissions for high blood glucoses. We will use data from this pilot work to inform a larger powered study to address this knowledge gap.",[258,259,29,228,31,30],[544],"Type 1 Diabetes Mellitus","2022-06-23",{"date":547,"type":40},"2022-06-24",{"date":549,"type":40},"2020-09-03",{"date":551,"type":21},"2022-06-30",{"name":553,"class":47},"Imperial College London"]